About the Company
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EDIT News
Editas Medicine gets grant for allele-specific modification of hla genes for cell transplantation
Enhance donor cell compatibility for transplantation with Editas Medicine's patented method. Reduce immunogenicity genes' expression for therapeutic benefits.
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the Company and Vertex Pharmaceuticals entered into a license agreement. Under terms of the ...
Editas Medicine, Inc. (8EM.F)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Editas Medicine Inc EDIT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Editas Medicine Inc EDIT
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Editas Medicine Inc (EDIT)
Gene editing firm Editas Medicine (EDIT +14.3%) shows some life ahead its Q2 report on Wednesday afternoon after the close. Consensus view is a loss of ($0.71) per share on ...
Editas Medicine Inc (EDIT)
View the EDIT option chain and compare options of Editas Medicine Inc stock. Analyze the various options available, including call options (the right to buy) and put options (the right to sell ...
Editas Medicine Inc (EDIT)
Investing.com - Editas Medicine reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Editas Medicine announced ...
Editas Medicine Inc (EDIT)
Editas Medicine (NASDAQ:EDIT) reported Q1 EPS of ($0.74), $0.05 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.77 million versus the ...
Loading the latest forecasts...